Reviewer’s report

Title: New uracil analog U-332 is an inhibitor of NF-κB in 5-fluorouracil-resistant human leukemia HL-60 cell line

Version: 0 Date: 15 Nov 2019

Reviewer: Sahil Sharma

Reviewer's report:

The manuscript entitled as "New uracil analog as an inhibitor of NF-κB in 5-fluorouracil-resistant human leukemia HL-60 cell line" submitted to the Journal "BMC Pharmacology and Toxicology" for publication. The manuscript is the follow up study of previous findings regarding uracil based compound U-332. The results are very interesting and the compound reported is active against the 5-FU resistant cell line i.e. HL-60/5FU. I recommend the article to be published in the journal after two minor revisions which are given below:

1. First line of the background section should be clubbed with "and".

2. Page-3, Line 27, "5-Fluorouracil (5-FU) was the first……. showed pharmacological activity" and Page-4, line 17, "The best known transporters that………. breast cancer resistance protein (ABCG2) should be modified.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I recommend additional statistical review
Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal